AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity
NervGen Pharma Corp. Common stock
XNAS · usd
SIC 3820
FIGI BBG00MMMWGD3
1.43▲ 0.01 (0.70%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
1.42
Day's Range
1.38 – 1.44
52-Week Range
1.38 – 6.30
Volume
944.0K
Avg Volume
463.6K
Share Statistics
Shares Outstanding
Employees
9
Exchange
XNAS
Listed
2019-03-25
Share count as of December 31, 2025

NervGen Pharma Corp. Common stock (NGEN) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about NervGen Pharma Corp. Common stock (NGEN)
What is NervGen Pharma Corp. Common stock's Market Cap?
NervGen Pharma Corp. Common stock's Market Cap is $113.9M, based on as-reported figures from SEC (XBRL) filings.
What is NervGen Pharma Corp. Common stock's Enterprise Value?
NervGen Pharma Corp. Common stock's Enterprise Value is $97.8M, based on as-reported figures from SEC (XBRL) filings.
What is NervGen Pharma Corp. Common stock's Net Income (TTM)?
NervGen Pharma Corp. Common stock's Net Income (TTM) is -$32.2M, based on as-reported figures from SEC (XBRL) filings.
What is NervGen Pharma Corp. Common stock's Diluted EPS (TTM)?
NervGen Pharma Corp. Common stock's Diluted EPS (TTM) is -0.40, based on as-reported figures from SEC (XBRL) filings.
What is NervGen Pharma Corp. Common stock's Net Debt?
NervGen Pharma Corp. Common stock's Net Debt is -$16.1M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · NGENAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of CAD, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024
Operating expenses
Research and development (Note 20)
General and administrative (Note 20)
Total operating expenses
Interest income
Unrealized loss on warrant derivative (Note 16)
Foreign exchange loss (gain)
Net loss